5 urologic oncology headlines you missed in Q2 2026

The second quarter of 2026 brought several practice-changing developments across genitourinary oncology, from new FDA approvals to pivotal phase 3 data presented at major scientific meetings. Advances in bladder, prostate, and kidney cancer expanded treatment options in both the adjuvant and perioperative settings while highlighting the growing role of biomarker-guided care and combination strategies.

Below is a roundup of 5 of the key urologic oncology stories from Q2 2026, including regulatory decisions, landmark clinical trial results, and emerging evidence that could influence treatment discussions and clinical decision-making for patients with genitourinary malignancies.

FDA approves atezolizumab as adjuvant therapy for MIBC guided by ctDNA

In May 2026, the FDA approved atezolizumab (Tecentriq) and atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) as adjuvant treatments for adults with muscle-invasive bladder cancer (MIBC) who have circulating tumor DNA molecular residual disease (ctDNA MRD), as determined by an FDA-authorized test.¹

This approval was supported by data from the phase 3 IMvigor011 trial (NCT04660344), which showed that atezolizumab significantly improved disease-free survival (DFS) compared with placebo among ctDNA-positive patients.² In patients who were ctDNA-positive, the median disease-free survival was 9.9 months with atezolizumab compared with 4.8 months with placebo (HR, 0.64; 95% CI, 0.47 to 0.87; P = .0047).

Click here to read the full article.

__

Aglatimagene plus radiotherapy improves prostate cancer-specific DFS

Data from the pivotal phase 3 PrTK03 trial (NCT01436968) showed that aglatimagene besadenovec (CAN-2409) combined with valacyclovir (prodrug) significantly extends DFS vs placebo plus valacyclovir when added to radiotherapy in patients with localized prostate cancer.³ At a median follow-up of 50.3 months, the addition of aglatimagene led to a 30% improvement in DFS (HR, 0.70; 95% CI, 0.52 to 0.94; P = .016) and a 38% improvement in prostate cancer-specific DFS vs placebo (HR, 0.62; 95% CI, 0.44 to 0.87; P = .0046).

These findings were presented at the 2026 American Urological Association Annual Meeting and subsequently published in The Lancet Oncology.

Click here to read the full article.

__

FDA approves durvalumab plus BCG for BCG-naïve, high-risk NMIBC

In May 2026, the FDA approved durvalumab (Imfinzi) in combination with BCG for the treatment of adult patients with BCG-naïve, high-risk non–muscle invasive bladder cancer (NMIBC).⁴ The approval was supported by data from the phase 3 POTOMAC trial (NCT03528694), which demonstrated that adding durvalumab to BCG induction and maintenance significantly improved disease-free survival (DFS) vs BCG induction and maintenance alone (HR, 0.68; 95% CI, 0.50 to 0.93; P = .0154).

Click here to read the full article.

__

PROTEUS: Apalutamide plus ADT before and after RP cuts metastasis risk

Data from the phase 3 PROTEUS trial (NCT03767244) were presented at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois.⁵ The study demonstrated that 1 year of perioperative apalutamide (Erleada) plus androgen deprivation therapy (ADT) combined with radical prostatectomy (RP) significantly improved metastasis-free survival, pathological complete response or MRD, event-free survival, and time to first subsequent therapy compared with placebo plus ADT with RP in patients with high-risk localized or locally advanced prostate cancer.

Click here to read the full article.

__

FDA approves adjuvant belzutifan with pembrolizumab for ccRCC

In June 2026, the FDA approved belzutifan (Welireg) in combination with pembrolizumab (Keytruda) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) as adjuvant regimens for adult patients with renal cell carcinoma with a clear cell component (ccRCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.⁶ The approval was supported by data from the phase 3 LITESPARK-022 study (NCT05239728), which met its primary end point by showing that the addition of belzutifan to adjuvant pembrolizumab significantly improved DFS vs pembrolizumab alone (HR, 0.72; 95% CI, 0.59 to 0.87; P = .0003).

Click here to read the full article.

See insights from Toni K. Choueiri, MD, on the approval here.

__

REFERENCES